The first antibody against CTLA-4, ipilimumab, was approved in 2011 (19), while pembrolizumab and nivolumab, antibodies that both target PD-1, were approved in 2014 for the treatment of melanoma (20, 21, 38). Here, CTLA4 is linked to melanoma.